Increased level of NEAT1 long non-coding RNA is detectable in peripheral blood cells of patients with Parkinson’s disease by Boros, Fanni Annamária et al.
Journal Pre-proofs
Research report
Increased level of NEAT1 long non-coding RNA is detectable in peripheral
blood cells of patients with Parkinson’s disease
Fanni Annamária Boros, Rita Török, László Vécsei, Péter Klivényi
PII: S0006-8993(20)30028-7
DOI: https://doi.org/10.1016/j.brainres.2020.146672
Reference: BRES 146672
To appear in: Brain Research
Received Date: 23 October 2019
Revised Date: 21 December 2019
Accepted Date: 12 January 2020
Please cite this article as: F. Annamária Boros, R. Török, L. Vécsei, P. Klivényi, Increased level of NEAT1 long
non-coding RNA is detectable in peripheral blood cells of patients with Parkinson’s disease, Brain Research (2020),
doi: https://doi.org/10.1016/j.brainres.2020.146672
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover
page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will
undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing
this version to give early visibility of the article. Please note that, during the production process, errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
© 2020 Published by Elsevier B.V.
1 Increased level of NEAT1 long non-coding RNA is detectable in peripheral blood cells of 
patients with Parkinson’s disease
Fanni Annamária Borosa, Rita Törökab, László Vécseiab, Péter Klivényia*
aDepartment of Neurology, Albert Szent-Györgyi Clinical Center, Faculty of Medicine, 
University of Szeged, Semmelweis u. 6. H-6725, Szeged, Hungary; 
bMTA-SZTE Neuroscience Research Group, Semmelweis u. 6. H-6725, Szeged, Hungary
*Corresponding author: 
Péter Klivényi, MD, PhD, DSc
Department of Neurology, Albert Szent-Györgyi Medical Center, Faculty of Medicine, 
University of Szeged 
P.O. Box: 427, H-670l, Szeged, Hungary
Tel/Fax: +36 62545-351; +36 62545-597
E-mail: klivenyi.peter@med.u-szeged.hu
The current work was supported by Hungarian Brain Research Program [Grant number 2017-
1.2.1-NKP-2017-00002 NAP VI/4] and by Economic Development and Innovation Operational 
Programme [Grant number GINOP-2.3.2-15-2016-00034]. 
The authors declare no conflict of interest regarding the publication of this article.
2Abstract
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder that poses 
serious burden to individuals and society as well. Although a number of PD associated genetic 
factors have been identified, the molecular mechanism of the disease so far has not been 
completely elucidated. Involvement of long non-coding RNAs (lncRNAs) in the pathology of 
neurodegenerative disorders is attracting increased interest because of the diverse mechanisms 
lncRNAs affect gene expression and cellular homeostasis at different levels. We aimed to test 
the feasibility of detecting alterations in lncRNA levels in easily accessible samples of PD 
patients by routine laboratory technique. By narrowing the number of selected lncRNAs 
implicated in neurodegeneration and increasing the number of PD samples included, we found 
one out of 41 lncRNAs readily detectable in increased level in peripheral blood of PD patients. 
We detected NEAT1 to be significantly up-regulated in PD patients in multiple comparisons. 
NEAT1 is the core element of nuclear paraspeckles and it plays role in regulation of 
transcription, mRNA and miRNA levels, mitochondrial and cellular homeostasis. Our finding 
is in accord with recent data demonstrating changes in the level of NEAT1 in neurons of PD 
patients and in several models of the disease. However, to our knowledge this is the first study 
to report NEAT1 up-regulation in blood of PD patients. Identification of altered expression of 
this lncRNA in the periphery might help to a better understanding of the mechanisms 
underlying PD, and can contribute to the identification of new therapeutic targets and disease 
markers.
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3Highlights: 
 NEAT1 lncRNA regulates cellular and mitochondrial homeostasis. 
 Changes in NEAT1 level were reported in PD brain and in models of the disease.
 We detected up-regulated NEAT1 level in leukocytes of PD patients.
 NEAT1 up-regulation was most prominent among patients with long disease duration.
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PINK1: PTEN-induced kinase 1
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51. Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting 
approximately 1-2% of the population over the age of 65 (Goedert, 2001). In PD leading motor 
symptoms, such as bradykinesia, rigidity, and tremor are often associated with non-motor 
symptoms, such as sleep- and mood disorders, depression and dementia. The progression of PD 
is a great burden for the patients, for their families and society as well. Although only a 
relatively small fraction of PD cases is familiar, a number of genetic factors are believed to 
play direct or indirect role in PD etiology. Among the Parkinson’s disease associated genes 
(PARK) identified so far several are involved in mitochondrial energy conversion, oxidative 
stress response and apoptosis (reviewed in (Benson and Huntley, 2019)). 
Long non-coding RNAs (lncRNAs) are frequently, although not obligatorily polyadenylated 
RNA polymerase II transcripts, which are over 200 nucleotides in length by definition with no 
identifiably open reading frame(s). In recent years lncRNAs attracted particular attention since 
they seem to play roles in regulating gene expression and cellular homeostasis at several levels 
and by diverse mechanisms. LncRNAs can modulate gene expression at transcriptional level by 
acting themselves as repressors or activators, by modulating regulatory factor availability, by 
serving as transcriptional co-factors, or by modulating RNA polymerase II activity. They can 
also act as post-transcriptional modulators by regulating mRNA availability, editing and 
degradation, or by modulating miRNA mediated functions ((Feng et al., 2006; Martianov et al., 
2007; Wang et al., 2008) for a review, see (Li et al., 2019)). Additionally, lncRNAs can exert 
regulation through epigenetic mechanisms (Brockdorff et al., 1992; Brown et al., 1992; Butler 
et al., 2019). Alterations in lncRNA levels have been shown in several neurological diseases. 
An increasing body of evidence is accumulating the involvement of lncRNAs in Alzheimer’s 
disease (AD), Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS) (D. Q. Wang 
et al., 2018) Furthermore, possible connections between specific non-coding transcripts and PD 
6have also been suggested: Soreq et al. investigated the lncRNA profile of PD patients’ 
leukocytes by whole transcriptome sequencing (Soreq et al., 2014). They found that over 6000 
detected leukocyte lncRNAs, 13 had altered expression in PD patients as compared to healthy 
controls. The majority of these lncRNAs - 8 out of 13 - showed increased expression. In the 
cases of four lncRNAs, deep brain stimulation (DBS) treatment resulted in a decrease in 
expression. According to this study RP11-462G22.1 (lnc-FRG1-3), an anti-sense transcript of 
the FRG1 gene, is significantly upregulated in PD. As the FRG1 gene is associated with 
facioscapulohumeral muscular dystrophy 1, the FRG1 lncRNA might contribute to the muscle 
rigidity seen in PD patients. Expression of the spliceosome component U1 was also 
significantly upregulated in PD samples supporting the notion that the modulation of splicing 
might be involved in the course of the disease (Soreq et al., 2014). Strong down-regulation of 
the Ubiquitin carboxy-terminal hydrolase L1 antisense transcript (Uchl1 AS) in in vitro and in 
vivo PD models was reported in 2015 by Carrieri and colleagues (Carrieri et al., 2015). Uchl1 
AS is transcribed on the same region but in opposite direction as the protein-coding UCHL1, 
alias PARK5 gene is, which has been shown to carry mutations in rare cases of early-onset 
familial PD. Moreover, the expression of Uchl1 AS is under the control of the transcription 
factor NURR1 that is involved in the maintenance and differentiation of dopaminergic cells and 
for which mutations have also been associated with PD (Grimes et al., 2006; Xu et al., 2002). 
Normally Uchl1 AS is located in the nucleus however, under certain stress conditions it is 
transported to the cytoplasm, where it facilitates UCHL1 mRNA expression, leading to a rise in 
the level of UCHL1 protein. The overexpression of the UCHL1 protein has a neuroprotective 
effect, thus the increased expression of Uchl1 AS can be part of a cell-salvage mechanism 
(Carrieri et al., 2015).
Recently, Kraus and colleagues compared lncRNA expression levels in brain tissue of PD 
patients and healthy control individuals (Kraus et al., 2017). They found that out of 90 non-
7coding transcripts investigated in their study only 5 had significantly altered levels in patients 
compared to healthy controls. The lncRNA H19 upstream conserved regions 1 and 2 were 
significantly downregulated, while lincRNA-p21, MALAT1 (Metastasis Associated Lung 
Adenocarcinoma Transcript 1), SNHG1 (Small Nucleolar RNA Host Gene 1), and NEAT1 
(alias TncRNA) were found to have increased expression. In line with these findings, more 
recently Simchovitz et al. reported a significant elevation in the expression level of NEAT1 in 
the substantia nigra of PD patients (Simchovitz et al., 2019).
With the aim to test the feasibility of detecting alterations in lncRNA using easily accessible 
samples by routine laboratory technique we compared leukocyte-derived lncRNA levels in PD 
patients. Data obtained by this approach might provide details on the pathological mechanism 
underlying this neurodegenerative disease and indicate the possibility of lncRNA detection as 
diagnostic marker.
Blood samples are accessible by minor invasive procedures and offer the possibility of a cheap, 
feasible and quick way of identifying disease-related biomarkers. Nucleated leukocytes are 
informative both in respect to genetic and gene expression analysis and have the advantage that 
they reflect the status and changes occurring throughout the body due to their interactions with 
most of the tissues and organs (Soreq et al., 2014). Experimental data show that impacts 
affecting the central nervous system, such as for example DBS, can cause changes in leukocyte 
gene expression (Soreq et al., 2012). Moreover, existing correlations demonstrated between 
peripheral blood-based and brain derived biomarkers in neuropsychiatric disorders (Harris et 
al., 2012), as well as identified blood-based biomarkers in AD (Fehlbaum-beurdeley et al., 
2012), multiple sclerosis (MS) (Nickles et al., 2013) and schizophrenia (Harris et al., 2012) 
provide grounds for attempting such investigations in the case of PD as well. In this respect it is 
important to note that while the prominent motor symptoms of PD are primarily due to the 
8neuronal loss in the central nervous system, more and more observations suggest that it has 
more systemic effects, influencing functions of the peripheral nervous system as well (Berstad 
and Berstad, 2017; Dzamko et al., 2015; Hawkes et al., 2007; Liu et al., 2003; Svensson et al., 
2015; Weller et al., 2005; Westfall et al., 2017). 
The data we report here indicate a significant increase in NEAT1 lncRNA level in peripheral 
blood cells of PD patients. This observation correlates well both with recently published data 
on the up-regulation of this lncRNA in PD models and tissue samples and also with the 
suggested role of NEAT1 lncRNA in cellular functions affected in PD such as mitochodrial 
homeostasis, oxidative stress response, apoptosis. (Simchovitz et al., 2019; Y. Wang et al., 
2018). Despite several recent reports on possible functions of NEAT1, whether it contributes 
primarily to neurodegeneration or neuroprotection is still unclear. It is well documented, that 
NEAT1 increases the stability of PINK1 protein, and by this, it facilitates mitophagy. As this 
might affect damaged and healthy mitochondria as well, this effect is considered more to be 
neurodegenerative (Oe et al., 2019)(Yan et al., 2018). On the other hand, in cellular and animal 
models, NEAT1 upregulation provides protection against oxidative stress of mitochondria by a 
LRRK2 mediated pathway, and based on this, its neuroprotective role is suggested (Simchovitz 
et al., 2019).
2. Results 
2.1. LncRNAs detectable in peripheral blood samples of PD patients
By reviewing literature data we selected 41 lncRNAs which have been implicated in 
neurodegenerative malignancies (Table 1.). Nine of these were directly linked to PD (RP11-
101C11.1, RP11-409K20.6, RP11-124N14.3, RP11-79P5.3, AC004744.3, RP11-542K23.9, 
PCA3 (Soreq et al., 2014), NEAT1 (Kraus et al., 2017; Simchovitz et al., 2019) and MALAT1 
9(Liu et al., 2017)), while others were associated with AD (BC200, BACE1-AS (Feng et al., 
2018; Lukiw et al., 1992)), HD (MEG3, TUG1 (Taurine Up-Regulated Gene 1), LINC00341, 
HAR-1A (Chanda et al., 2018; Johnson, 2012; Johnson et al., 2010; Wang et al., 2014)), and/or 
were found to be involved in mechanisms that are likely related to neurodegeneration. We 
attempted to detect these lncRNAs in peripheral blood cells of controls and PD patients (n=3 in 
each group) by qRT-PCR. Those lncRNAs, which had a Ct larger than 35 we excluded from 
the further analysis since the low expression level makes their detection by this technique 
unreliable. The levels of lncRNAs deemed to be detectable in our first approach were compared 
within larger groups of healthy and PD samples (n=15 and 18, respectively) (validation study 
I.). In this comparison we found the level of lncRNAs BC200, PTENP1-AS (Phosphatase and 
Tensin Homolog Pseudogene 1 Antisense RNA) and MEG3 to be below reliable detection level 
(Ct over 35). These RNAs therefore were omitted from the further analysis. The expression 
level of GAS5 showed minimal variation in both PD and control samples, therefore we selected 
GAS5 as an internal control for reference. Stable expression of GAS5 lncRNA has also been 
noted by both Santoro et al. and Kraus et al. (Kraus et al., 2017; Santoro et al., 2016). Applying 
GAS5 normalization, we found the expression of NEAT1 significantly up-regulated among PD 
patients (fold increase=1.93; p=0.035) compared to the control group (Table 2.). Similarly, we 
detected a significant up-regulation of the lncRNA TUG1 by comparing PD patients to the 
control cohort (fold increase=1.71; p=0.036) (Table 2.). Besides NEAT1 and TUG1, no other 
lncRNA was found to exhibit a significant difference in expression in comparison between this 
PD group and control cohort.
2.2. Comparison of NEAT1 and TUG1 lncRNA levels between study groups including 
larger number PD patients and controls
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Based on the findings of validation study I., we investigated the expression of NEAT1 and 
TUG1 lncRNAs in study groups including larger number PD patients (n=43) and controls 
(n=36) (validation study II.). Applying GAS5 normalization, we found significant up-
regulation of NEAT1 expression among PD patients compared to controls (fold increase= 1.62; 
p=0.0019) (Suppl. Table 1., Figure 1.) As DBS treatment was reported to influence lncRNA 
expression in leukocytes (Soreq et al., 2012), we compared our samples in respect of this 
treatment. The difference in NEAT1 expression between healthy control and PD patients was 
significant both in comparisons including and not including DBS patients (fold increase= 1.61 
and 1.62; p=0.0021 and 0.0071, respectively) (Suppl. Table 1., Figure 1B and C). Between 
patients with- and without DBS we did not find significant difference in NEAT1 level (Suppl. 
Table 1., Figure 1.). NEAT1 expression was significantly up-regulated as compared to the 
control group in both EOPD and LOPD group (fold change= 1.5 and 1.82; p=0.0181 and 
0.0073, respectively). Between the EOPD and LOPD group however, there was no significant 
difference in NEAT1 level (Suppl. Table 1., Figure 1E-G,). Comparison of female PD patients 
to female control individuals revealed significantly up-regulated NEAT1 level among PD 
patients (fold increase= 1.72; p= 0.0073). Though the difference was not significant, up-
regulation could also be observed among male PD patients compared to control male 
individuals (Suppl. Table 1., Figure 2H and I).
Comparison between subgroups SDD and LDD indicated slightly up-regulated NEAT1 level 
among patients of the LDD group, however, the difference was not significant. Comparisons of 
subgroups of SDD and LDD patients to the control group revealed significant up-regulated 
NEAT1 RNA levels in both cases (fold change= 1.57 and 1.74; p= 0.028 and 0.0008, 
respectively) with more prominent NEAT1 up-regulation among LDD patients (Suppl. Table 
1., Figure 2J-L.). 
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After performing Bonferroni correction the difference remained significant in pair wise 
comparisons between the control group and PD group-,or patients with DBS or the LDD group.
In the expression of TUG1 we detected no significant difference in either of the comparisons 
described above (Suppl. Table 2.).
3. Discussion
With this study, we aimed to identify alterations in lncRNA expression in PD that could help to 
understand the underlying disease mechanisms, may help to find potential therapeutic targets, 
and can be potential biomarker for diagnosis. Our aim was also to use easily accessible sample 
to this analysis and reliable experimental approach that is readily available in a clinical 
laboratory. We selected for a first comparison 41 lncRNAs which have been reported to be 
related to neurodegenerative diseases. Among these 7 lncRNAs (indicated in bold in Table 1.) 
had already been reported by Soreq et al. to have altered expression in PD (Soreq et al., 2014). 
From these 7 lncRNAs, we detected only 2 (RP11-409K20.6 and RP11-124N14.3) by our 
assay, the other 5 had a Ct >40 (indicated in italics in Table 1.). The difference between our and 
the published data could be explained by the different methods used for expression monitoring: 
while Soreq and colleagues carried out whole-transcriptome RNA-Seq analysis, we used real-
time PCR. Another explanation could be in a high inter-individual expression variability of 
lncRNAs (Kornienko et al., 2016), and also the small number of analysed samples. Based on 
the data from this preliminary study we selected 12 lncRNAs for comparison involving a larger 
sample number (validation study I.). In this analysis we detected low expression levels for 
BC200, PTENP1-AS, and MEG3, therefore these transcripts had to be considered undetectable. 
Our failure to detect these lncRNAs is unlikely because of technical reason. BC200 lncRNA is 
expressed predominantly in the brain, specifically in the hypothalamus, but shows low, or no 
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expression in other tissues (Castle et al., 2010; Tiedge et al., 1993). MEG3 is a candidate 
tumour suppressor. According to lncRNA database (http://www.lncrnadb.org) MEG3 is not 
expressed in human white blood cells. PTENP1-AS also acts as a tumour suppressor. Poliseno 
and colleagues, described relatively low levels of PTENP1-AS under physiological conditions 
in various human tissues, including peripheral blood leukocytes (Poliseno et al., 2010). In our 
assays the average Ct of the PTENP1-AS transcript was only slightly above the threshold (37.2 
± 1.2 in the control group, and 37.9 ± 2 among PD patients).
Out of the well detectable 9 neurodegeneration-related lncRNAs, we found NEAT1 and TUG1 
to be significantly up-regulated in PD patients compared to control group. We tested the 
expression of these two lncRNAs in a third set of samples (validation study II.). Results on this 
larger number of PD and control groups however revealed no significant difference in the 
expression of TUG1 between PD patients and non-PD controls. TUG1 lncRNA acts as 
transcriptional repressor, that upon DNA damage suppresses the progression of the cell-cycle 
(Khalil et al., 2009). It achieves this by forming PcG bodies (Polycomb group protein 
containing nuclear repressive foci) on the promoters of cell cycle genes in interaction with a 
component of the Polycomb Repressive complex 1 (PRC1) (Yang et al., 2011). With respect to 
neurodegenerative diseases, TUG1 was found to be up-regulated in HD (Johnson, 2012), but no 
other data have been reported regarding TUG1 expression in neurodegenerative diseases, 
including PD.
We found NEAT1 to be significantly up-regulated in PD patients in multiple comparisons. The 
most prominent differences were observable by comparing all PD patients to all control 
individuals (fold change= 1.62; p= 0.0019), PD patients with DBS to the control group (fold 
change= 1.61; p= 0.0021), and LDD patients’ group to control group (fold change= 1.74; p= 
0.0008). In each of these comparisons the difference remains significant after Bonferroni 
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correction. In the case of comparison of PD patients with DBS to controls however, the small 
sample size of PD patients should be taken into account. The finding that the expression of 
NEAT1 was significantly up-regulated among LDD patients compared to control individuals 
suggests that the amount of the lncRNA increases with disease progression. This novel notion 
could be interesting in relation to PD pathology, however, whether the change in NEAT1 level 
is coincidental or in causative relation with disease progression remains to be explored.
In either way, NEAT1 elevated expression in PD patients deserves attention because this 
lncRNA has been shown to modulate cellular functions by several mechanisms and it might 
affect disease pathology via a number of these.
NEAT1 lncRNA is expressed in two forms: a 3756 nucleotide long NEAT1_1, also known as 
MEN ε, and as a 27 kb long NEAT1_2, alias MEN β. Although the smaller form corresponds to 
the 5’ end of the longer and both NEAT1 isoforms are involved in paraspeckle formation, the 
two differ in functions (Sunwoo et al., 2009). In this study we used primers which target the 
5’region of NEAT1, consequently permit the detection of both NEAT1 isoforms.
NEAT1 lncRNA was first identified as a virus inducible gene product that was up-regulated in 
mouse central nervous system after virus infection (Saha et al., 2006). More recent data 
demonstrated that HIV-1 (Zhang et al., 2013), influenza virus and herpes simplex virus 
infection also enhanced NEAT1 expression, and NEAT1 promoted the expression of antiviral 
genes, such as Interleukin-8 (IL-8) (Imamura et al., 2014). The involvement of NEAT1 in 
inflammatory processes raises the possibility that this lncRNA plays role in the reported 
increase of inflammatory markers in the peripheral blood of PD patients (King and Thomas, 
2017). Recently various mechanisms have been described by which NEAT1 regulates cellular 
functions. Most of the effects mediated by NEAT1 are due its involvement in paraspeckle 
formation. Paraspeckles are approximately 0.5 µm size membraneless subnuclear particles 
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consisting of a large number of proteins and NEAT1 RNAs as a scaffold. Paraspeckles are 
responsible for the retention of the A-to-I hyperedited mRNAs in the nucleus (Mao et al., 
2011). Through this they play a pivotal role in cellular response to stress. Under cellular stress 
conditions, such as transcription inhibition or exposure to the combination of 
lipopolysaccharide and interferon-γ, specific A-to-I hyperedited RNA types can be rapidly 
transported into the cytoplasm where they are used for protein synthesis (Prasanth et al., 2005). 
By this mechanisms the cell produces a rapid stress response since it can save time by not 
synthesizing de novo mRNAs, but using already synthesized transcripts for protein synthesis in 
order to respond to stress stimuli (Nakagawa and Hirose, 2012). By retaining hyperedited 
mRNAs in the nucleus paraspeckles play role in cell differentiation as well (Bond and Fox, 
2009). Recently NEAT1 involvement in regulating mitochondrium homeostasis through the 
nuclear retention of mRNAs encoding proteins with mitochondrial function (mito-mRNA) has 
been shown. Paraspeckle-enriched mito-RNAs exhibited enhanced nucleo-cytoplasmic export 
in NEAT1 knockout cell suggesting a quality control mechanism that prohibit unnecessary 
translation of mito-mRNAs following stress (Y. Wang et al., 2018). Paraspeckles also regulate 
gene expression by retaining regulatory proteins. Sequestration and/or liberation of 
transcription factors to and from paraspeckles offer rapid ways for modulating gene expression.
The possible roles of NEAT1 in the human central nervous system attracted attention in the last 
decade. Investigation of human nucleus accumbens samples of heroin abusers showed a 
significant up-regulation of the gene as compared to drug-free controls (Michelhaugh et al., 
2011). The association of NEAT1 lncRNA expression with neurodegenerative diseases was 
also examined in ALS (Nishimoto et al., 2013), HD (Johnson, 2012) and PD (Kraus et al., 
2017). In 2013 Nishimoto and colleagues reported that NEAT1_2 transcript was up-regulated 
in ALS patients compared to the control group (Nishimoto et al., 2013). Similarly, NEAT1 up-
regulation was found in HD patients (Johnson, 2012). According to a recent study by Kraus et 
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al., the lncRNA NEAT1 was significantly up-regulated in the anterior cingulate gyrus of PD 
patients as well as compared to healthy controls (Kraus et al., 2017). More recently Simchovitz 
et al. reported significant up-regulation of NEAT1 in the substantia nigra (SN) of PD patients 
compared to non-PD controls. In the SN, dopaminergic neurons were identified as the main 
NEAT1 expressers and paraspeckle forming cells. Cell culture and murine model studies 
showed that under oxidative stress conditions the expression of the NEAT1 transcript was 
enhanced. Genetic ablation of NEAT1 led to a reduction in the number of paraspeckle forming 
cells and also in the number of paraspeckles in the nucleus, together with a diminishment in the 
survival of cells pre-treated with oxidative stress agents (Simchovitz et al., 2019).
Interconnection between several PD associated genes and NEAT1 lncRNA has been 
demonstrated in a number of PD models. Mutations of the gene encoding LRRK2 protein is 
among the most frequently identified genetic alterations in both familial and sporadic PD 
(Kumari and Tan, 2009). LRRK2 is involved in mitophagy and LRRK2 mutation delays the 
arrest of dysfunctional mitochondria (see (Grünewald et al., 2019)). Simchovitz and colleagues 
showed that NEAT1 could serve as a natural inhibitor of LRRK2 by retaining it in paraspeckles 
through its interaction with non-POU domain containing octamer binding (NONO) and splicing 
factor proline glutamine rich (SFPQ) proteins (Simchovitz et al., 2019).
Studies of MPTP/MPP+ induced mouse and cell culture models of PD yielded seemingly 
contrasting results regarding the role of NEAT1 in the course of PD. Recent studies involving 
murine and cell models reported up-regulation of NEAT1 after treatment with MPTP or MPP+, 
accompanied by decreased cell viability. On the other hand, genetic inhibition of NEAT1 
promoted cell survival (Geng et al., 2019; Liu and Lu, 2018; Yan et al., 2018). Various 
mechanisms have been described by which NEAT1 regulates apoptosis, oxidative stress and 
neuroinflammation (Figure 2.). Yan et al. showed that in PD mice both NEAT1 and a PD 
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susceptibility gene, PTEN-induced kinase 1 (PINK1) expression was up-regulated. In vitro 
findings revealed that whereas genetic ablation of NEAT1 significantly decreased the otherwise 
enhanced apoptosis rate following MPP+ treatment and down regulated PINK1 expression, 
overexpression of the lncRNA inhibited the cycloheximide induced degradation of PINK1. The 
beneficial effects of NEAT1 knockdown were abolished via overexpressing PINK1. Based on 
these findings the authors proposed that by direct binding to PINK1, NEAT1 stabilizes the 
protein, thus mediates autophagy and neuronal injury (Yan et al., 2018). NEAT1 down-
regulation was also found to decrease α-synuclein expression, and ablation of the lncRNA in 
SH-SY5Y cells increased cell viability. However, up-regulation of α-synuclein reversed the 
beneficial changes in apoptosis rate upon genetic inhibition of NEAT1 (Liu and Lu, 2018). 
NEAT1 was also proposed to take part in the course of PD via a miR-221 related mechanism. 
Recent findings revealed miR-221 down-regulation in serum samples of PD patients and 
proposed its potential role as a biomarker for the disease (Ding et al., 2016; Ma et al., 2016). 
The expression of the micro RNA was also found to be reduced in cellular models of PD and 
overexpression of miR-221 promoted cell viability. A direct target of miR-221 is PTEN 
(Phosphatase and tensin homolog deleted on chromosome 10) which in addition to its 
tumorsuppressor function also has been linked to the pathogenesis of neurodegenerative 
disorders such as AD, ALS and PD (Ismail et al., 2012). Recently a study of SH-SY5Y cells 
revealed the down-regulation of miR-221 in parallel with NEAT1 up-regulation following 
MPP+ treatment (Geng et al., 2019). On the opposite, NEAT1 knockdown caused increased 
expression of the micro RNA. Overexpressing miR-221 prior to MPP+ treatment led to a 
decrease in ROS generation, LDH release and down-regulation of IL-1β, IL-6 and TNFα. 
NEAT1 was identified as a molecular sponge for miR-221 that observation led to the 
conclusion that MPP+ induced neuronal damage alleviation by NEAT1 ablation was partly due 
to the decreased sponging of miR-221 by NEAT1 (Geng et al., 2019).
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All combined NEAT1 seems to be in a central position to regulate several of those cellular 
functions which have been shown to be altered in PD. To determine, which of the effects 
exerted by NEAT1 through modulating mitochondrial homeostasis, apoptosis, stress response, 
mRNA and miRNA availability are specific to unique cells in the central nervous system or 
mediate functions of different cell types, among them white blood cells, requires further 
studies. Nonetheless, the change of NEAT1 level in peripheral blood cells in PD patients can be 
well accommodated with the described roles of the lncRNA and the effects it shows in PD 
models. However, whether the changes of NEAT1 levels that we observed in blood cells of PD 
patients are consequential or in causative relation with the disease needs further elucidation. 
Answer to this question should be sought with keeping in mind the recent shift in the paradigm 
of PD aetiology that instead of viewing the disease specific to the central nervous system views 
it as a systemic ailment.
4. Conclusions
In easily accessible peripheral blood cells of PD patients we detected an increased NEAT1 
lncRNA level. In light of the diverse mechanisms by which NEAT1 affects cellular functions, 
the increased level of the lncRNA can be causally or coincidently linked to PD. Change in 
NEAT1 lncRNA expression in brain tissue of PD patients has been reported recently (Kraus et 
al., 2017; Simchovitz et al., 2019). Our finding that the change in NEAT1 level can be detected 
in blood samples might open possibilities to find signs of developing PD by investigating 
samples more easily accessible than the nervous tissue. By uncovering the cause and effects of 
the change of NEAT1 level in PD progression could lead to a better understanding of the 
underlying mechanisms of the disease and to the identification of new potential therapeutic 
targets to interfere with this devastating neurodegeneration.
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5. Experimental procedure
5.1. Study design
For a preliminary study we selected 41 lncRNAs, each of which has been implicated in 
neurodegenerative disease (Table 1.) and examined their levels in blood cells of a small number 
of PD patient versus control samples (n=3 and 3) with real-time polymerase chain reaction 
(RT-PCR). Based on this preliminary result we narrowed the set of neurodegeneration-related 
lncRNAs to 12 (validation study I., Table 2.) and analysed the expression levels of these 
lncRNAs in a second, larger group of PD patients and non-PD controls (n=18 and 15). Based 
on the results of these assays 2 lncRNAs out of the 12 were selected for further study and the 
level of these was investigated a third larger group of patients and controls consisting 43 and 36 
individuals, respectively (validation study II.). 
5.2. Participiants
Both PD patients and non-PD volunteers were Hungarians of Caucasian origin. The diagnosis 
of PD was set up based on medical history and physical examination carried out by movement 
disorder specialists. Individuals with known other malignancies or with cancerous disease in 
their history were excluded. Validation study group I. composed of 9 women and 9 men, the 
mean age of the cohort was 60.3±5.7 years. The average age at disease onset was 52.5±5.6 
years. Validation study group II consisted of 43 PD patients. The mean age of this group of 
patients was 63.3±11.4 years, the male/female ratio: 24/19, the average age at disease onset was 
54.8±12.6 years. Out of the 43 participants, 6 reported first symptoms to appear before the age 
of 40 years (mean age at disease onset 35±7.8 years). One of these patients reported the 
possibility of positive family history regarding PD: the main symptom of this participant was 
left side dominant tremor, and tremor was reported to be present in family members both of the 
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maternal and paternal side, however, to our knowledge no definite diagnosis of PD was set up 
for the relatives. Genetic screening of this patient (pathogenic LRRK2, parkin and DJ-1 
mutations) yielded negative results.
For data analysis patients were further divided into two cohorts: the early onset PD group 
(EOPD) consisted those, who had a disease onset before or at the age of 60 years (n=27; age: 
57.6±9.8 years), while the late onset PD group (LOPD) consisted those with disease onset after 
60 years (n=16; age: 73±5.9 years). The average age at the onset of the disease in EOPD and 
LOPD groups was 47.5±10.2 and 66.5±4.0 years, respectively. Based on disease duration (DD) 
patients were also separated into two subgroups. Out of the 42 patients, 27 belonged to the 
‘short DD’ (SDD) subgroup with DD <10 years (age: 62.9±11.9 years, DD: 4.9±2.8 years), 
while the ‘long DD’ - DD≥10 years - subgroup (LDD) consisted of 15 individuals (age: 
63.7±10.9 years, DD: 14.6±5.0 years). One patient had to be excluded from this analysis as no 
information was available upon DD. In validation study I. there were no patients who had DBS 
treatment. Among PD patients of validation study II., 8 out of 43 participants had gone under 
DBS surgery (PD DBS n=8, age: 64.3±7.1 years; PD no DBS n=35, age: 63.1±12.2 years).
Out of the 43 PD patients 26 individuals went under genetic testing regarding the monogenic 
forms of the disease ((LRRK2; parkin and DJ-1), of which all tests yielded negative results.
The majority of patients - 30 out of 43 - presented tremor. Modified Hoehn and Yahr scale 
varied between 1 and 5, mean 1.9±0.8. UPDRS motor score of the patients at the time of 
sample collection ranged from 2 to 48 points, the mean score was 12±8.9 points. 36 out of 43 
PD patients received levodopa as treatment, and the mean time of treatment duration at sample 
collection was 6.4 ±4.1 years. Further details of clinical data are presented in Supplementary 
Table 4.
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In validation study I. control group, the male/female ratio was 6 to 9, and the mean age was 
61.3±9.9 years. The validation study II. control group consisted of 36 individuals (male/female: 
16/20), the mean age was 57.6±18.0 years (for detailed demographic data see Suppl. Table 3.).
Before participating, informed consent was obtained from each participant included in the 
study. The study protocol was approved by the Medical Research Council Scientific and 
Research Ethics Committee and was in full accordance with the Declaration of Helsinki ethical 
principles for medical research involving human subjects.
5.3. Methods
Blood samples were collected from members of patient and control groups in EDTA containing 
blood tubes. White blood cells of 5 ml blood samples were separated by centrifugation and 
lysed in 1 ml of TRI Reagent (Sigma) by repetitive pipetting within 2 hours of collection. 
Samples were then stored at -80oC. Total RNA isolation was carried out following the Trizol 
RNA purification protocol according to the manufacturer’s instructions (Sigma). RNA 
concentration was determined with a MaestroNano micro-volume spectrophotometer. In the 
preliminary and first validation study complementary DNA (cDNA) was synthesized from 500 
ng of extracted RNA with the use of RT2 First Strand Kit (Qiagen) following the 
manufacturer’s instructions. Real-timePCR was performed with the use of RT2 SYBR Green 
Mastermix (Qiagen). Equal volumes of cDNA samples were aliquoted into the wells of a 
specifically designed Custom RT2 PCR Array (Qiagen) containing lncRNA specific primer 
pairs (25 ul final volume). Two arrays were designed and used for the groups of 41 and 12 
lncRNAs (Table 1 and 2, respectively). 
For validation study II commercially available NEAT1 and TUG1 gene-specific primers were 
used (Qiagen). cDNA was synthesized from 1000 ng of RNA with the use of Revert Aid First 
Strand cDNA Synthesis Kit (Thermo Scientific). Real-time PCR was performed with the use of 
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RT2 SYBR Green Mastermix (qPCRBIO) in 25 µl final volume. PCR reactions were carried 
out in a CFX96 thermocycler (Bio-Rad). Cycling conditions are available upon request. 
5.4. Data analysis and statistics
Statistical analysis of PCR results was performed using RT2 PCR analysis web portal 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php) and GraphPad Prism 6.01 
statistics software using the ΔΔCt method. In short, ΔCt was calculated as the difference 
between a gene of interest and the average of reference gene, ΔΔCt was calculated as ΔCt 
(patient) – average ΔCt (control) and fold change was determined as 2-ΔΔCt value (Livak and 
Schmittgen, 2001). For the identification of the outliers among 2-ΔΔCt replicates the ROUT 
method was used. D’Agostino and Pearson omnibus normality test was used for the analysis of 
data distribution. If the data showed normal distribution, we implemented unpaired t-test, while 
in the case of non-normal distribution Mann-Whitney U test was performed. P value under 0.05 
was considered significant. Due to the multiple comparisons, Bonferroni correction was 
implemented. Following this, p value under 0.004 was considered significant.
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Figure 1. Comparisons of NEAT1 lncRNA level between controls (n=36) and PD patients 
(n=43) and their subgroups. Fold regulation are shown with standard deviation. Significant 
up-regulation of NEAT1 expression was detected in comparisons between PD and control 
group (A), PD patients with or without DBS and control group (B and C). Comparison 
between patients with and without DBS does not shown significant difference in NEAT1 
level (D). NEAT1 was found to be significantly upregulated in EOPD and LOPD groups 
as compared to control group (E and F), while no significant difference was detected 
between EOPD and LOPD patients (G). NEAT1 was found to be up-regulated both in 
female PD to female control and male PD to male control comparisons (H and I), however 
the difference was not significant in the latter. Neither was significant difference 
detectable in NEAT1 level between SDD and LDD patient groups (J). NEAT1 was found 
significantly up-regulated in comparisons between both SDD and LDD groups and 
controls (K and L). The difference of NEAT1 expression between PD group vs. control 
group, patients with DBS vs. control group and LDD vs. control group remained 
significant after Bonferroni correction.
Abbreviations: PD: Parkinson’s disease; Ctrl: control; DBS: deep brain stimulation; EOPD: 
early onset Parkinson’s disease; LOPD: late onset Parkinson’s disease; SDD: short disease 
duration; LDD: long disease duration; ns.: non-significant; *: p<0,05; **: p<0,01; ***: 
p<0,001; #: p value significant after Bonferroni correction.
Figure 2. Mechanisms by which NEAT1 might effect cell viability and PD.
NEAT1 lncRNA, a major constituent of paraspeckles, plays divers regulatory roles by 
modulating the availability of mRNAs, miRNAs and transcription factors. By the nuclear 
retention of mito-mRNAs - mRNAs encoding proteins with mitochondrial function – NEAT1 
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directly affects mitochondrium homeostasis. (Y. Wang et al., 2018).
In the pathogenesis of PD (boxed) NEAT1 was suggested to participate by regulating 
autophagy, neuroinflammation and neuronal cell injury via stabilizing PINK1 (Yan et al., 
2018), influencing SNCA expression (Liu and Lu, 2018) and sponging miR-221 (Geng et al., 
2019). NEAT1 was also proposed to be a bona fide LRRK2 inhibitor acting via its nuclear 
retention (Simchovitz et al., 2019).
Abbreviations: NEAT1: Nuclear paraspeckle assembly transcript 1; PINK1: PTEN-induced 
kinase 1; SNCA: α-synuclein; LRRK2: Leucine-rich repeat kinase 2; mito-mRNAs: messenger 
RNAs encoding proteins with mitochondrial function.
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Figure 1. Comparisons of NEAT1 lncRNA level between controls (n=36) and PD patients 
(n=43) and their subgroups.
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Figure 2. Mechanisms by which NEAT1 might effect cell viability and PD.
Sponging of miR-221
PINK1 stabilization 
NEAT1
Modulation of the availability of mito-
mRNAs, mRNAs, miRNAs and 
transcriptional regulators 
LRRK2 inhibition (?)Modulation of gene expression and mitochondrial homeostasis
NEAT1
SNCA
Increase of α synuclein expression 
PINK1NEAT1
NEAT1
miR-221
NEAT1 LRRK2
Modulation of cell 
viability
Paraspeckle formation
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Table 1. Neurodegeneration implicated lncRNAs included in the perliminary study (control 
n=3, PD n=3).
Bold: lncRNAs reported to have altered expression in PD (Soreq et al., 2014). Italics: lncRNAS 
detected in low level (Ct>40), bold: lncRNAs, which were reported to have altered expression 
in PD by Soreq and collegues (Soreq et al., 2014).
RP11-101C11.1 BCYRN1 (BC200) DLX6-AS1
RP11-409K20.6 ATXN8OS PTENP1-AS
SCOC-AS1 BDNF-AS MALAT1
RP11-124N14.3 HAR1A HOXA11-AS
RP11-79P5.3 HAR1B HOXA-AS2
LOC339568 NEAT1 HOXA-AS3
AC004744.3 DGCR5 MEG9
RP11-542K23.9 MEG3 TUNAR
LOC338797 TUG1 TMEM161B-AS1
PCA3 LINC00341 ST7-AS1
LINC01262 MTOR1-AS1 ST7-AS2
UCHL1-AS1 GAS5 RBM5-AS1
SOX2-OT HOTAIR LINC00853
BACE-AS1 SIX3-AS1
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Table 2. LncRNAs included in validation study I. (control n=15, PD n=18) and their expression 
changes.
LncRNAs detected in Ct >35 were excluded from further analysis. 
Abbreviations: PD: Parkinson’s disease; Ctrl: control.
       Average Ct
Gene Symbol PD Ctrl
Fold change
(PD/ Ctrl)
P value
RP11-409K20.6 34.21 34.63 1.53 0.88
GAS5 27.73 27.53 n.a. n.a.
RP11-124N14.3 34.36 34.73 1.48 0.95
LINC00341 33.77 34.31 1.66 0.55
PINK1-AS 34.23 34.93 1.86 0.79
NEAT1 26.70 27.46 1.93 0.035*
MALAT1 31.95 32.36 1.52 0.07
MTOR-AS1 34.96 34.97 1.15 0.57
TUG1 30.35 30.93 1.71 0.037*
BC200 >35  >35 n.a. n.a.
PTENP1-AS >35 >35 n.a. n.a.
MEG3 >35 >35 n.a. n.a.
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Supplementary Table 1.
Fold regulation of NEAT1 in validation study II.  
NEAT1
 
Fold regulation p Statistical test Bonferroni corr. (p< 0.0042)
PD total (n=43) vs. Ctrl total (n=34) 1.62 0.0019** Mann-Whitney U test significant
PD no DBS (n=35) vs. Ctrl total (n=34) 1.62 0.0072** Mann-Whitney U test ns.
PD DBS (n=8) vs. Ctrl total (n=34) 1.61 0.0021** unpaired t test significant
PD DBS (n=8) vs. PD no DBS (n=35) 0.99 0.53 Mann-Whitney U test ns.
PD male (n=24) vs. Ctrl male (n= 16) 1.35 0.1 Mann-Whitney U test ns.
PD female (n=19) vs. Ctrl female (n=19) 1.72 0.0073** unpaired t test ns.
EOPD (n=27) vs. Ctrl total (n=34) 1.5 0.0181* Mann-Whitney U test ns.
LOPD (n=16) vs. Ctrl total (n=34) 1.82 0.0113* unpaired t test ns.
EOPD (n=27) vs. LOPD (n=16) 0.83 0.32 Mann-Whitney U test ns.
SDD (n=27) vs. LDD (n=15) 0.9 0.33 Mann-Whitney U test ns.
SDD (n=27) vs. Ctrl total (n=34) 1.57 0.028* Mann-Whitney U test ns.
LDD (n=15) vs. Ctrl total (n=34) 1.74 0.0008*** Mann-Whitney U test significant
39
Abbreviations: NEAT1: Nuclear Paraspeckle Assembly Transcript 1; PD: Parkinson’s disease; Ctrl: control; DBS: deep brain stimulation; 
EOPD: early onset Parkinson’s disease; LOPD: late onset Parkinson’s disease; SDD: short disease duration; LDD: long disease duration; *: 
p<0,05; **: p<0,01; ***: p<0,001.
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Supplementary Table 2.
Fold regulation of TUG1 in validation study II.  
TUG1
 Fold regulation p Statistical test
PD total (n=43) vs. Ctrl total (n=36) 0.98 0.84 unpaired t test
PD no DBS (n=35) vs. Ctrl total (n=36) 0.98 0.83 unpaired t test
PD DBS (n=8) vs. Ctrl total (n=36) 0.99 0.98 unpaired t test
PD DBS (n=8) vs. PD no DBS (n=35) 1.02 0.98 unpaired t test
PD male (n=24) vs. Ctrl male (n= 16) 0.92 0.44 unpaired t test
PD female (n=19) vs. Ctrl female (n=20) 1.05 0.71 unpaired t test
EOPD (n=27) vs. Ctrl total (n=36) 0.9 0.22 unpaired t test
LOPD (n=16) vs. Ctrl total (n=36) 1.12 0.26 unpaired t test
EOPD (n=27) vs. LOPD (n=16) 0.8 0.057 unpaired t test
SDD (n=27) vs. LDD (n=15) 0.91 0.42 unpaired t test
SDD (n=27) vs. Ctrl total (n=36) 0.95 0.57 unpaired t test
LDD (n=15) vs. Ctrl total (n=36) 1.05 0.63 unpaired t test
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Abbreviations: TUG1: Taurine Up-Regulated Gene 1; PD: Parkinson’s disease; Ctrl: control; DBS: deep brain stimulation; EOPD: early onset 
Parkinson’s disease; LOPD: late onset Parkinson’s disease; SDD: short disease duration; LDD: long disease duration.
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Supplementary Table 3.
Demographic data of participants involved in validation studies I. and II. 
Validation Study I.     
 n (male/female) Age (mean ± SD; years) Age at disease onset (mean ± SD; years) Disease duration (mean ± SD; years)
Ctrl 15 (6/9) 61.3±9.9 n.a. n.a.
PD 18 (9/9) 60.3±5.7 52.5±5.6 7.8±5.8
     
Validation Study II.     
 n (male/female) Age (mean ± SD; years) Age at disease onset (mean ± SD; years) Disease duration (mean ± SD; years)
Ctrl total 36 (16/20) 57.6±18 n.a. n.a.
PD total 43 (24/19) 63.3±11.4 54.8±12.6 8.4±6
PD DBS 8 (6/2) 64.3±7.1 53.7±10.6 9.7±4.6
PD no DBS 35 (18/17) 63.1±12.2 55±13.1 8.1±6.2
EOPD 27 (14/13) 57.6±9.8 47.5±10.2 9.6±6.7
LOPD 16 (10/6) 73±5.9 66.5±4 6.4±4
SDD 27 (15/12) 62.9±11.9 58±10.8 4.9±2.8
LDD 15 (8/7) 63.7±10.9 49.1±13.9 14.6±5
Abbreviations: Ctrl: control; PD: Parkinson’s disease; DBS: deep brain stimulation; EOPD: early onset PD; LOPD: late onset PD; SDD: short 
disease duration; LDD: long disease duration. 
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Supplementary Table 4. 
Clinical characteristics of participants involved in validation study II.
Family history of PD
yes/no 4/39
Presence of tremor
yes/no 30/13
Modified Hoehn and Yahr scale
PD total (n=43) (mean±SD) 1.9±0.8
1 10 (23.3%)
2 21 (48.8%)
2.5 9 (21%)
3 1 (2.3%)
4 1 (2.3%)
5 1 (2.3%)
UPDRS motor score
PD total (n=43) (mean±SD) 12±8.9
<10 22 (51.2%)
10-20 16 (37.2%)
>20 5 (11.6%)
Applied medication at the time of sample collection
Levodopa 36 (83.7%)
other (ropinirole, entacapone, razagiline) 3 (7%)
none 4 (9.3%)
Levodopa treatment duration at the time of sample collection 
PD total (n=36) (mean years±SD) 6.4 ±4.1
<5 years 13 (36.1%)
5-10 years 17 (47.2%)
>10 years 6 (16.7%)
Abbreviations: PD: Parkinson’s disease.
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Highlights: 
 NEAT1 lncRNA regulates cellular and mitochondrial homeostasis.
 Changes in NEAT1 level were reported in PD brain and in models of the disease.
 We detected up-regulated NEAT1 level in leukocytes of PD patients.
 NEAT1 up-regulation was most prominent among patients with long disease duration.
